Abstract
We evaluate effect of levodopa–carbidopa intestinal gel(LCIG, carbidopa-levodopa enteral suspension[CLES] in USA)on motor and nonmotor symptoms in a multi-country observational study in advanced Parkinson's disease (PD) patients treated with LCIG in routine clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have